Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335328 · ClinicalTrials.gov registry record · Phase 1
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07335328 is a Phase 1 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 24 participants.
The verdict
NCT07335328, a Phase 1 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
Interventions
- BIOLOGICAL 1 X 10^6 cells/kg
- BIOLOGICAL 2.5 X 10^6 cells/kg
- BIOLOGICAL Dose expansion: The maximum tolerated dose of CAR-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07335328
The ClinicalTrials.gov registry entry for NCT07335328 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 1 X 10^6 cells/kg is the first listed.
NCT07335328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07335328 about?
NCT07335328 is a clinical study titled "Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies". This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
What is the current status of trial NCT07335328?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-09-01. Estimated completion is 2031-05-01.
What interventions are being tested in trial NCT07335328?
The interventions under investigation include: 1 X 10^6 cells/kg (BIOLOGICAL), 2.5 X 10^6 cells/kg (BIOLOGICAL), Dose expansion: The maximum tolerated dose of CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07335328?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.